These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. Beck A; Reichert JM MAbs; 2013; 5(5):621-3. PubMed ID: 23924791 [TBL] [Abstract][Full Text] [Related]
4. Trends in capacity utilization for therapeutic monoclonal antibody production. Langer ES MAbs; 2009; 1(2):151-6. PubMed ID: 20061821 [TBL] [Abstract][Full Text] [Related]
6. Study critiques corporate control of trials. Niiler E Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659 [No Abstract] [Full Text] [Related]
7. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? Moorkens E; Vulto AG; Huys I MAbs; 2020; 12(1):1743517. PubMed ID: 32306833 [TBL] [Abstract][Full Text] [Related]
9. First biosimilar drug approved for sale in the United States. Hede K J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142444 [No Abstract] [Full Text] [Related]
10. The state of biopharmaceutical manufacturing. Molowa DT; Mazanet R Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933 [TBL] [Abstract][Full Text] [Related]
20. 10 years of biosimilars: lessons and trends. Royzman I; Shah K Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591 [No Abstract] [Full Text] [Related] [Next] [New Search]